☰

Julie M. Madden, Ph.D. - Publications

Affiliations: 
2014 Cancer Biology Wayne State University, Detroit, MI, United States 
Area:
Oncology, Cell Biology
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Purrington K, Dyson G, Craig D, Boerner J, Madden J, Beebe-Dimmer J, Schwartz AG, Simon M. Abstract 4175: Spectrum of heritable mutations in 43 known and candidate breast cancer susceptibility genes in African American women with breast cancer Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4175  0.369
2018 Colacino JA, Azizi E, Brooks MD, Harouaka R, Fouladdel S, McDermott SP, Lee M, Hill D, Madden J, Boerner J, Cote ML, Sartor MA, Rozek LS, Wicha MS. Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports. PMID 29606612 DOI: 10.1016/J.Stemcr.2018.03.001  0.352
2014 Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. Breast Cancer Research and Treatment. 147: 283-93. PMID 25129346 DOI: 10.1007/S10549-014-3102-8  0.473
2014 Madden J, Mueller K, Bollig-Fischer A, Stemmer P, Boerner J. EIF4B as a Novel Target in EGFR Expressing Triple Negative Breast Cancer Annals of Oncology. 25: i21. DOI: 10.1093/Annonc/Mdu069.3  0.472
2013 Madden J, Mueller K, Bollig-Fischer A, Stemmer P, Boerner J. Abstract 1026: Combating resistance to EGFR inhibitors: eIF4B as a novel target. Cancer Research. 73: 1026-1026. DOI: 10.1158/1538-7445.Am2013-1026  0.595
2012 Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL. EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK. Translational Oncology. 5: 327-34. PMID 23066441 DOI: 10.1593/Tlo.12163  0.552
2012 Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Research : Bcr. 14: R104. PMID 22788954 DOI: 10.1186/Bcr3224  0.583
2012 Madden J, Mueller K, Bollig-Fischer A, Stemmer P, Boerner J. Abstract 1068: Inhibition of the phosphorylation of eIF4 molecules sensitizes EGFR expressing breast cancers to EGFR inhibitors Cancer Research. 72: 1068-1068. DOI: 10.1158/1538-7445.Am2012-1068  0.609
Show low-probability matches.